James McLoughlin, MD
Surgical Oncology · Knoxville, TNNPI 1376745653
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 60.9% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $4,919 and has fallen 89.9% since, to $495 in 2025.
Across 140 payments — averaging $52.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Medtronic$517
- Merck$491
- Takeda Pharmaceuticals U.S.A., Inc.$181
- AbbVie$178
- Covidien LP$97
- plus $1K from 34 others
What the payments were for
- Speaking & faculty fees$1502%
- Travel & lodging$1,03414%
- Food & beverage$3,13543%
- Education$3,00041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $4,456 |
| Medtronic | 8 | $517 |
| Merck | 35 | $491 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $181 |
| AbbVie(2 entities) | 9 | $178 |
| Covidien LP | 2 | $97 |
| Novartis | 4 | $91 |
| Eisai Inc. | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 4 | $83 |
| Genentech USA, Inc. | 5 | $80 |
| AstraZeneca | 3 | $73 |
| Biocompatibles, Inc. | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 5 | $65 |
| GSK | 3 | $60 |
| Promega Corporation | 1 | $59 |
| Incyte Corporation | 4 | $58 |
| Teleflex LLC | 2 | $57 |
| Lilly USA, LLC | 4 | $54 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| Boston Scientific | 3 | $51 |
| Pfizer | 3 | $49 |
| Galvanize Therapeutics, Inc | 1 | $49 |
| Seagen Inc. | 3 | $43 |
| Aroa Biosurgery Incorporated | 1 | $41 |
| Tempus AI, Inc | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $28 |
| TELA Bio, Inc. | 1 | $24 |
| Caris MPI, Inc. | 1 | $20 |
| Polynovo North America LLC | 1 | $19 |
| Syndax Pharmaceuticals, Inc. | 1 | $19 |
| Kerecis Limited | 1 | $18 |
| Gilead | 1 | $17 |
| Stryker | 1 | $16 |
| Adaptive Biotechnologies Corporation | 1 | $15 |
| Amgen | 1 | $15 |
| Acera Surgical, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Axogen | 1 | $12 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Mallinckrodt Enterprises LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,128
- Signia$276
- GATTEX$150
- LigaSure$114
How this compares
$7,319 in reported general payments places this provider in the 75th percentile of 53 surgical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 31 | $101,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $178 | $101,09231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 53 surgical oncology providers in Tennessee.
Other surgical oncology in Knoxville
- James LewisKnoxville$45K
- David RoifeKnoxville$13K
- Troy KimseyKnoxville$4K
- Laura EnomotoKnoxville$2K
- Ryan SchmockerKnoxville$2K
- Gregory MidisKnoxville$2K
- Jillian LloydKnoxville$1K
- Ana WilsonKnoxville$835
- John BellKnoxville$570
- Keith GrayKnoxville$539
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.